StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research report report published on Monday. The firm issued a hold rating on the medical research company’s stock.
Accelerate Diagnostics Stock Performance
Shares of AXDX stock opened at $1.77 on Monday. The company has a market cap of $39.03 million, a P/E ratio of -0.43 and a beta of 0.61. Accelerate Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $6.39. The stock has a 50 day simple moving average of $1.75 and a two-hundred day simple moving average of $1.35.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. The company had revenue of $2.99 million during the quarter, compared to the consensus estimate of $3.00 million. On average, research analysts predict that Accelerate Diagnostics will post -2.14 earnings per share for the current year.
Hedge Funds Weigh In On Accelerate Diagnostics
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Further Reading
- Five stocks we like better than Accelerate Diagnostics
- How is Compound Interest Calculated?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- When to Sell a Stock for Profit or Loss
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- NYSE Stocks Give Investors a Variety of Quality Options
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.